Immunocore Holdings plc
About Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $400.0M
- Net income
- -$35.5M
- Total assets
- $1.1B
- Market cap
- $1.4B
- Gross margin
- 98.7%
- Operating margin
- -11.3%
- Net margin
- -8.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $400.0M
- Cost of revenue
- $5.1M
- Gross profit
- $394.9M
- Operating expenses
- $440.3M
- Operating income
- -$45.4M
- Income tax
- $16.4M
- Net income
- -$35.5M
- EPS (basic)
- $-0.71
- EPS (diluted)
- $-0.71
Balance sheet
- Total assets
- $1.1B
- Current assets
- $996.7M
- Total liabilities
- $686.2M
- Current liabilities
- $246.7M
- Shareholders’ equity
- $381.0M
Cash flow
- Operating cash flow
- -$10.7M
- Investing cash flow
- -$16.3M
- Financing cash flow
- $12.4M
- Net cash flow
- $12.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-0.71
- Shares outstanding
- 51.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 5, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $35.5M in FY2025.
- Revenue grew 60% from FY2023 to FY2025.
- Gross margin of 98.7%, net margin -8.9%.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immunocore Holdings plc.
Write a review
News about Immunocore Holdings plc
News & sentiment via Polygon.io
